Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Holding THNR?
Track your performance easily
THNR Price & Analysis
THNR ETF Chart & Stats
Day’s Range― - ―
52-Week Range$24.92 - $28.19
Previous Close$26.44
VolumeN/A
Average Volume (3M)3.01K
AUM4.77M
NAV26.46
Expense Ratio0.59%
Holdings Count31
Beta0.79
Inception DateMay 21, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Shares Outstanding180,000
Standard Deviation0.05
10 Day Avg. Volume2,018
30 Day Avg. Volume3,014
Alpha-0.02
Amplify Weight Loss Drug & Treatment ETF (THNR) Fund Flow Chart
Amplify Weight Loss Drug & Treatment ETF (THNR) 1 year Net Flows: $5M
THNR ETF News
THNR ETF FAQ
What was THNR’s price range in the past 12 months?
THNR lowest ETF price was $24.92 and its highest was $28.19 in the past 12 months.
What is the AUM of THNR?
As of Oct 15, 2024 The AUM of THNR is 4.77M.
Is THNR overvalued?
According to Wall Street analysts THNR’s price is currently Undervalued.
Does THNR pay dividends?
THNR does not currently pay dividends.
How many shares outstanding does THNR have?
THNR has 180,000 shares outstanding.
Which hedge fund is a major shareholder of THNR?
Currently, no hedge funds are holding shares in THNR
THNR ETF Smart Score
Learn more about TipRanks Smart Score
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.
Top 10 Holdings
Eli Lilly And Company
15.18%
Novo Nordisk
13.40%
Roche Holding
5.29%
Pfizer Inc
5.23%
Chugai Pharmaceutical Co
5.14%
AstraZeneca
5.11%
Amgen Inc
5.10%
Thermo Fisher Scientific
5.07%
Merck & Company
5.02%
FUJIFILM Holdings Corp
4.76%
Total69.31%
ETF Description
Amplify Weight Loss Drug & Treatment ETF
THNR tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses.